Phibro Animal Health (PAHC) Stock Price, News & Analysis

Company Overview

Phibro Animal Health Corporation develops, manufactures and sells products designed to support the health, nutrition and productivity of food-producing animals. Its offerings include animal health products, vaccines, medicated feed additives, nutritional specialties and performance products used in livestock, poultry and aquaculture.

The company’s products are intended to help prevent and manage disease, improve animal well-being and support efficient food production. Phibro serves producers, veterinarians, feed manufacturers and distributors through a portfolio that includes pharmaceuticals, vaccines, mineral and nutritional supplements, and other feed and water solutions.

Phibro Animal Health markets its products internationally across a broad range of geographic regions, including North America, Latin America, Europe, Asia-Pacific and other global markets. The company was founded in 1916 and is headquartered in Teaneck, New Jersey.

Key Stats

• Today's Range: $33.07 to $35.01
• 50-Day Range: $32.96 to $39.92
• 52-Week Range: $28.25 to $60.08
• Volume: 110,343 shs
• Average Volume: 281,435 shs
• Market Capitalization: $1.40 billion
• P/E Ratio: 13.77
• Dividend Yield: 1.39%
• Price Target: $46.50
• Consensus Rating: Buy

Phibro Animal Health Stock Analysis - MarketRank™

Phibro Animal Health scored higher than 90% of companies evaluated by MarketBeat, and ranked 27th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Phibro Animal Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Phibro Animal Health has a consensus price target of $46.50, representing about 34.6% upside from its current price of $34.54.

Amount of Analyst Coverage

Phibro Animal Health has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.03%

Earnings Growth

Earnings for Phibro Animal Health are expected to grow by 10.03% in the coming year, from $3.49 to $3.84 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Phibro Animal Health is 13.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.50.

Price to Earnings Ratio vs. Sector

The P/E ratio of Phibro Animal Health is 13.75, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.92.

Price to Book Value per Share Ratio

Phibro Animal Health has a P/B Ratio of 3.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.94% of the float of Phibro Animal Health has been sold short.

Short Interest Ratio / Days to Cover

Phibro Animal Health has a short interest ratio ("days to cover") of 4.31.

Change versus previous month

Short interest in Phibro Animal Health has recently increased by 1.14%, indicating that investor sentiment is decreasing.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Phibro Animal Health pays a meaningful dividend of 1.46%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Phibro Animal Health does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Phibro Animal Health is 19.12%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Phibro Animal Health will have a dividend payout ratio of 12.50% next year. This indicates that Phibro Animal Health will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.51

News Sentiment

Phibro Animal Health has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Phibro Animal Health this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for PAHC on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Phibro Animal Health insiders have not sold or bought any company stock.

Percentage Held by Insiders

48.47% of the stock of Phibro Animal Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.34% of the stock of Phibro Animal Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 9/23 Dividend: 9/02/2026
• Ex-Dividend for 9/23 Dividend: 9/02/2026
• Dividend Payable: 9/23/2026
• Last Earnings: 11/04/2026
• Today: 11/09/2026
• Record date for 12/16 Dividend: 11/25/2026
• Ex-Dividend for 12/16 Dividend: 11/25/2026
• Dividend Payable: 12/16/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PAHC
• CIK: 1069899
• Web: www.pahc.com
• Phone: (201) 329-7300
• Fax: 201-329-7399
• Employees: 2,605
• Year Founded: 1946

Price Target and Rating

• Average Price Target for Phibro Animal Health: $46.50
• High Price Target: $49.00
• Low Price Target: $44.00
• Potential Upside/Downside: +34.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.51
• Trailing P/E Ratio: 13.75
• Forward P/E Ratio: 9.00
• P/E Growth: N/A
• Net Income: $99.72 million
• Net Margins: 6.66%
• Pretax Margin: 9.08%
• Return on Equity: 35.88%
• Return on Assets: 9.16%

Debt

• Debt-to-Equity Ratio: 1.70
• Current Ratio: 3.20
• Quick Ratio: 1.28

Sales & Book Value

• Annual Sales: $1.52 billion
• Price / Sales: 0.92
• Cash Flow: $4.79 per share
• Price / Cash Flow: 7.21
• Book Value: $9.50 per share
• Price / Book: 3.64

Miscellaneous

• Outstanding Shares: 40,600,000
• Free Float: 20,922,000
• Market Cap: $1.40 billion
• Optionable: Optionable
• Beta: 0.42